- Director Crombez Eric sold 26,143 shares of Abeona Therapeutics Inc. for approximately $144,645.00.
- Abeona Therapeutics Inc. (NASDAQ: ABEO) reported $8.70 million in net product revenue for ZEVASKYN in Q1 2026, treating five commercial patients.
- The biopharmaceutical company is expanding its Qualified Treatment Centers (QTCs), activating the Children’s Hospital of Philadelphia as its sixth QTC, and holds $168.30 million in cash and investments.
Abeona Therapeutics Inc. is a biopharmaceutical company that develops gene and cell therapies for serious diseases. Its main focus is on its commercial product, ZEVASKYN, a treatment for a rare and severe skin disorder known as recessive dystrophic epidermolysis bullosa (RDEB). The biopharmaceutical company is actively expanding its treatment network for this gene and cell therapy.
Amidst recent company developments, a director at Abeona Therapeutics Inc., Crombez Eric, sold 26,143 shares on May 15, 2026. The shares were sold at a price of $5.53 each, resulting in a total transaction value of approximately $144,645.00. After this insider stock sale, Crombez Eric’s remaining holding in the company stands at 37,313 shares.
This insider transaction occurs as Abeona Therapeutics Inc. reports early commercial progress for ZEVASKYN. During its first quarter of 2026, the company generated $8.70 million in net product revenue from three treatments. CEO Dr. Vishwas Seshadri confirms that five commercial patients have been treated since the product’s launch, with manufacturing for a sixth patient now underway.
To support its primary focus, Abeona Therapeutics Inc. is expanding its network of Qualified Treatment Centers (QTCs). As highlighted by GlobeNewswire, the company recently activated the Children’s Hospital of Philadelphia as its sixth QTC. This expansion increases patient access to ZEVASKYN, particularly on the East Coast, and is a key part of its commercial strategy.
Financially, Abeona Therapeutics Inc. reported holding $168.30 million in cash, cash equivalents, and short-term investments as of March 31, 2026. Abeona is also making strategic pipeline changes, such as in-licensing a new T-cell technology for solid tumors while deprioritizing its ophthalmology programs to concentrate resources on its core objectives.
